Compare IVVD & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVVD | CDNA |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 692.7M | 712.2M |
| IPO Year | 2021 | 2014 |
| Metric | IVVD | CDNA |
|---|---|---|
| Price | $2.22 | $18.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $8.33 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 11.9M | 1.1M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | $50,039,000.00 | ★ $357,998,000.00 |
| Revenue This Year | $103.88 | $12.73 |
| Revenue Next Year | $171.40 | $11.90 |
| P/E Ratio | ★ N/A | $14.14 |
| Revenue Growth | ★ 332.71 | 14.46 |
| 52 Week Low | $0.35 | $10.96 |
| 52 Week High | $3.07 | $26.37 |
| Indicator | IVVD | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.88 | 64.49 |
| Support Level | $2.09 | $17.11 |
| Resistance Level | $2.60 | $18.20 |
| Average True Range (ATR) | 0.25 | 0.75 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 41.67 | 94.68 |
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.